Aspira Pathlab P/E Ratio
Current P/E Ratio
53.69
High Valuation
Very High - High growth expectations or significantly overvalued
Aspira Pathlab P/E ratio. Aspira Pathlab (ASPIRA) P/E ratio is 53.69 (High), EPS (TTM) ₹1.97, current price ₹119.15 on BSE — Very High - High growth expectations or significantly overvalued. Examine ASPIRA quarterly results for recent quarterly revenue, profit and EPS trends.
Current Valuation Metrics
P/E Ratio
53.69
Current Price
₹119.15
EPS (TTM)
₹1.97
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
94.31
Sector Median
43.09
Sector Rank
#11 of 57
Sector Percentile
19.3%
Earnings Breakdown (TTM)
TTM EPS
₹1.54
Mar 2025
₹0.66
Jun 2025
₹0.41
ASPIRA P/E Ratio — Valuation Signal & Historical Context
Aspira Pathlab P/E 53.69 — signal: Overvalued. For live price, revenue and the complete fundamental profile, see Aspira Pathlab share price screener.
- Stock appears overvalued with PE of 53.69, suggesting caution for new investments
- Trading at discount to sector average PE of 94.31
ASPIRA vs Healthcare Services Peers — P/E Ratio Comparison
Aspira Pathlab P/E 53.69 vs Healthcare Services average 94.31, median 43.09 — range 6.97–1642.14.
Sector Average
94.31
Sector Median
43.09
Lowest P/E
6.97
Highest P/E
1642.14
Companies
57
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Star Imaging And Path Lab | STARIMAGIN | 6.97 | ₹131 | Low |
| Abate AS Industries | ABATEAS | 10.23 | ₹122 | Low |
| Deccan Health Care | DECCAN | 11.6 | ₹29 | Low |
| Nidan Labs & Healthcare | NIDAN | 11.94 | ₹17 | Low |
| One Global Service Provi… | ONEGLOBAL | 13.97 | ₹1,027 | Low |
| Shanmuga Hospital | SHANMUGA | 14.42 | ₹61 | Low |
| Indraprastha Medical Cor… | INDRAMEDCO | 16.52 | ₹3,061 | Moderate |
| Invicta Diagnostic | INVICTA | 17.24 | ₹85 | Moderate |
| Dhanvantri Jeevan Rekha | ZDHJERK | 18.19 | ₹9 | Moderate |
| Krsnaa Diagnostics | KRSNAA | 18.62 | ₹1,793 | Moderate |